Cargando…

Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer

Despite the significant contribution of radiotherapy to non-small lung cancer (NSCLC), radioresistance still occurs. One of the major radioresistance mechanisms is the hyperactivation of the PI3K/Akt pathway in which Akt facilitates the repair of DNA double-strand breaks (DSBs) through the stimulati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toulany, Mahmoud, Iida, Mari, Keinath, Simone, Iyi, Firdevs F., Mueck, Katharina, Fehrenbacher, Birgit, Mansour, Wael Y., Schaller, Martin, Wheeler, Deric L., Rodemann, H. Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190057/ https://www.ncbi.nlm.nih.gov/pubmed/27248324 http://dx.doi.org/10.18632/oncotarget.9670

Ejemplares similares

Akt1 and Akt3 but not Akt2 through interaction with DNA-PKcs stimulate proliferation and post-irradiation cell survival of K-RAS-mutated cancer cells
por: Toulany, Mahmoud, et al.
Publicado: (2017)

Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers
por: Tiwari, Aadhya, et al.
Publicado: (2020)

Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation
por: Toulany, Mahmoud, et al.
Publicado: (2011)

Akt1 Stimulates Homologous Recombination Repair of DNA Double-Strand Breaks in a Rad51-Dependent Manner
por: Mueck, Katharina, et al.
Publicado: (2017)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012)

K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo
por: Hofmann, Irmgard, et al.
Publicado: (2012)

Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectives
por: Toulany, Mahmoud
Publicado: (2022)

Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells
por: Holler, Marina, et al.
Publicado: (2016)

Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells
por: Jin, W, et al.
Publicado: (2003)

Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
por: García-Echeverría, Carlos
Publicado: (2008)

Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K
por: Pallegar, Nikitha K., et al.
Publicado: (2015)

Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
por: Dong, Mingjie, et al.
Publicado: (2018)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
por: Butler, Dominika E., et al.
Publicado: (2017)

K-ras/PI3K-Akt Signaling Is Essential for Zebrafish Hematopoiesis and Angiogenesis
por: Liu, Lihui, et al.
Publicado: (2008)

Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers
por: Engelman, Jeffrey A., et al.
Publicado: (2008)

Does Ras Activate Raf and PI3K Allosterically?
por: Nussinov, Ruth, et al.
Publicado: (2019)

The Importance of Being PI3K in the RAS Signaling Network
por: Cuesta, Cristina, et al.
Publicado: (2021)

Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells
por: Maier, Eva, et al.
Publicado: (2019)

Nanog Signaling Mediates Radioresistance in ALDH-Positive Breast Cancer Cells
por: Dehghan Harati, Mozhgan, et al.
Publicado: (2019)

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
por: Jokinen, Elina, et al.
Publicado: (2012)

Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway
por: Wu, C-H, et al.
Publicado: (2002)

Oncogenic K-Ras Activates p38 to Maintain Colorectal Cancer Cell Proliferation during MEK Inhibition
por: van Houdt, Winan J., et al.
Publicado: (2010)

eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors
por: Hijazi, Maruan, et al.
Publicado: (2022)

Killer K-Ras
por: Powell, Kendall
Publicado: (2006)

K-RAS Is…Complicated
por: Clark, Geoffrey J.
Publicado: (2023)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer
por: Blas, Kevin, et al.
Publicado: (2018)

Selection Study for B+- -> (K-+ pi+- pi-+ pi+-)D K+- and B+- -> (K+ K- pi+ pi-)D K+-".
por: Hunt, P, et al.
Publicado: (2009)

Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway
por: Thang, Nguyen Dinh, et al.
Publicado: (2015)

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations
por: Rittler, Dominika, et al.
Publicado: (2020)

Dual Targeting of MEK and PI3K Pathways Attenuates Established and Progressive Pulmonary Fibrosis
por: Madala, Satish K., et al.
Publicado: (2014)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy
por: Chang, Raymond, et al.
Publicado: (2019)

Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells
por: Du, Wei, et al.
Publicado: (2021)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells
por: Zhao, Chengguang, et al.
Publicado: (2015)

The investigation of $K^+\pi^−, \pi^+K^−$ and $\pi^+\pi^−$ atoms
por: Yazkov, Valeriy
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_esahugva753mtk205h0n9sd42l